NanoVibronix, Inc. (NAOV)
NASDAQ: NAOV · Real-Time Price · USD
0.8556
-0.3244 (-27.49%)
At close: May 28, 2025, 4:00 PM
1.460
+0.604 (70.64%)
Pre-market: May 29, 2025, 6:06 AM EDT

Company Description

NanoVibronix, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, and wound healing, and administration at home without the assistance of medical professionals.

Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use.

The company also offers UroShield Ultra, which is designed to prevent bacterial colonization and biofilm formation in urinary catheters; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm and joint contractures.

In addition, it provides PainShield MD, a single patch-based therapeutic ultrasound technology to treat pain, muscle spasm and joint contractures; PainShield Plus, a dual patch-based therapeutic ultrasound technology; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing.

The company sells its products directly to patients, as well as through distributor agreements in the United States, Europe, Australia, Israel, New Zealand, and internationally.

NanoVibronix, Inc. was incorporated in 2003 and is based in Tyler, Texas.

NanoVibronix, Inc.
NanoVibronix logo
Country United States
Founded 2003
Industry Medical Devices
Sector Healthcare
Employees 31
CEO Brian Murphy

Contact Details

Address:
969 Pruitt Ave
Tyler, Texas 77569
United States
Phone 914 233 3004
Website nanovibronix.com

Stock Details

Ticker Symbol NAOV
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001326706
CUSIP Number 63008J108
ISIN Number US63008J6038
SIC Code 3842

Key Executives

Name Position
Brian M. Murphy Chief Executive Officer and Director
Dr. Harold Jacob M.D. Chief Medical Officer
Lindsey Harrison Vice President of Sales

Latest SEC Filings

Date Type Title
May 20, 2025 10-Q Quarterly Report
May 19, 2025 SCHEDULE 13G Filing
May 16, 2025 8-K Current Report
May 16, 2025 424B4 Prospectus
May 15, 2025 NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB
May 15, 2025 SCHEDULE 13G/A Filing
May 14, 2025 EFFECT Notice of Effectiveness
May 14, 2025 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
May 12, 2025 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Apr 29, 2025 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933